Professor Robert A. Kyle
A Pioneer in Amyloidosis and a Giant of Hematology
The International Society of Amyloidosis (ISA) mourns the passing of Professor Robert A. Kyle, M.D.—an exceptional physician-scientist, teacher, mentor, and colleague whose contributions shaped the modern field of amyloidosis and whose leadership was central to the Society’s founding. His death marks the loss of one of modern hematology’s most influential figures. Over more than six decades, Dr. Kyle transformed our understanding of plasma cell disorders and helped establish the scientific and clinical foundations on which amyloidosis care and research stand today.
Dr. Kyle was born in Bottineau, North Dakota. After graduating from Northwestern University Medical School in Chicago in 1952, he began an internship at Evanston Hospital—a path that ultimately brought him to Mayo Clinic in August 1961. He went on to play a major role in shaping many of the organizations that define our field today, including the International Society of Amyloidosis, the International Myeloma Society, the International Myeloma Foundation, and the International Waldenström’s Macroglobulinemia Foundation. For ISA, Dr. Kyle holds a particularly important place in our history. When the International Society of Amyloidosis was formally founded in 2002, he became its first President and later served as President of the Society’s first elected Board from 2004 to 2006. Under his leadership, ISA was established as a formal international organization with bylaws and a clear mission to advance amyloidosis research, education, clinical investigation, and international scientific exchange. The global Society we know today—bringing together investigators, clinicians, and members of the amyloidosis community from around the world—owes much to the foundation Bob and his colleagues created.
Dr. Kyle’s engagement with amyloidosis began early in his career, when an encounter with a patient initially thought to have multiple myeloma led him to undertake a systematic study of primary systemic amyloidosis. Over the decades that followed, his careful clinical observations and landmark studies helped define the clinical manifestations, natural history, and relationship of AL amyloidosis to monoclonal plasma cell disorders. At Mayo Clinic, he established an amyloidosis research program that became an internationally recognized center for the study and care of patients with this disease. His influence extended across the full spectrum of plasma cell disorders, including multiple myeloma, monoclonal gammopathy of undetermined significance, and Waldenström macroglobulinemia.
Dr. Kyle published widely, contributing more than 1,050 articles and book chapters and more than 1,350 abstracts to the medical literature. He received numerous honors, including the Robert A. Kyle Lifetime Achievement Award from the International Myeloma Foundation, the Robert A. Kyle Award from the IWMF, and the Robert A. Kyle Award for Outstanding Clinician Scientist from Mayo Clinic. He also received Mayo Clinic’s Henry S. Plummer Distinguished Internist Award, Distinguished Clinician Award, and Distinguished Alumni Award. He had the rare distinction of being one of only two people to receive both the David A. Karnofsky Memorial Award from the American Society of Clinical Oncology and the Wallace H. Coulter Award from the American Society of Hematology. These honors reflect an extraordinary scientific career, but those who knew Bob will remember equally his generosity, humility, intellectual curiosity, and unwavering commitment to patients and colleagues.
The International Society of Amyloidosis honors Robert A. Kyle with profound gratitude for the community he helped build, the knowledge he gave us, and the generations of physicians and scientists he inspired. His legacy will remain woven into the history and future of ISA and of amyloidosis worldwide.
